Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

CJC-1295 Side Effects: Phase 2 Trial Data Breakdown (2026)

IGF-1 Elevation as a Pharmacologic Signal CJC-1295's GHRH agonism produces dose-proportional GH elevation, which raises IGF-1. The 1.5-3x baseline IGF-1 elevation in trial reports is the pharmacologic mechanism, not an adverse event per se — but it informs the

By Recovery & Performance Peptides Editorial Team

IGF-1 Elevation as a Pharmacologic Signal

CJC-1295's GHRH agonism produces dose-proportional GH elevation, which raises IGF-1. The 1.5-3x baseline IGF-1 elevation in trial reports is the pharmacologic mechanism, not an adverse event per se — but it informs the monitoring pattern community sources commonly describe.

FDA labeling for the related tesamorelin product recommends IGF-1 monitoring. Community sources for CJC-1295 commonly describe IGF-1 measurement at baseline, 4-8 weeks, and 16-24 weeks; dose reduction is described when IGF-1 exceeds the lab's upper reference range.

Self-Reported Community Adverse Events

Note on labeling: the events below come from r/peptides, r/PeptideTherapy, and peptide forums for subcutaneous CJC-1295 use (both DAC and non-DAC versions).

Injection-site reactions

The most consistent community feedback. Mild redness, itching, or a small welt at the subcutaneous injection site, typically lasting under 24 hours.

Facial flushing within 10-20 minutes

Community sources commonly describe a brief warmth and visible flush after subcutaneous injection, particularly in the first weeks of use. Self-reported community sources describe injection-site rotation and slower injection speeds reducing severity.

Hand or face fluid retention

Self-reported community timelines describe mild fluid retention — particularly noticeable in the hands and around the face — during the first 2-4 weeks at higher doses. The pattern is more pronounced with CJC-1295 with DAC and resolves with dose reduction or cycling.

Hand tingling or numbness

Community reports cluster around transient hand tingling at higher doses, attributed by community sources to GH-induced fluid retention causing median-nerve compression. This is a documented GH-pharmacology finding (carpal tunnel-pattern symptoms in tesamorelin Phase 3 — see tesamorelin side effects).

Vivid dreams or sleep changes

Most consistent community feedback for evening administration is vivid dreams or restless sleep in the first week. Some users describe deeper sleep; others describe early-morning waking.

DAC vs Non-DAC Differences in Community Reports

GH/IGF-1 elevation

Pulsatile (hours)

Sustained (5-8 days)

Water retention reports

Less common

More common

Hand tingling

Sleep disruption

Cycle length community-typical

Continuous daily

1-2x weekly

The DAC version's longer half-life produces a different exposure pattern, which maps to a different community-reported event profile.

Dose-Response Patterns

Phase 1/2 trials tested CJC-1295 with DAC at single doses ranging from 30-250 mcg/kg (PMID 16352683). Dose-proportional GH and IGF-1 elevation was observed across that range. Community-reported research-peptide doses cluster around 100-300 mcg per dose (non-DAC, daily or twice-daily) or 1-2 mg per dose (DAC, 1-2x weekly).

Self-reported community sources describe injection-site reactions and fluid retention scaling with daily dose; serious events remain rare in community reports at typical doses.

Dose-Pause and Discontinuation Patterns

Phase 1/2 protocols allowed dose-interruption for severe injection-site reactions, IGF-1 elevations above protocol thresholds, and protocol-defined laboratory abnormalities. Community sources describe two patterns. Pause-and-resume — short breaks when hand-tingling or fluid retention becomes intrusive. Dose-cycling — 8-12 weeks on, 4 weeks off, citing IGF-1 normalization during off-cycles.

Core Supplies for This Protocol

The three essentials for running any reconstituted injectable: cold storage, accurate syringes, and metabolic tracking.

Cooluli Classic 4L Mini Fridge

Compact thermoelectric mini-fridge with heat/cool toggle. The most-mentioned dedicated peptide-storage fridge in research community sources — fits ~20 vials and runs quietly.

BD Ultra-Fine 31G 0.3cc 5/16" Insulin Syringes (Box of 90)

0.3cc 31G syringes — each gradation marks 1 unit (vs 2 units on 1cc), making sub-50-unit peptide doses accurate. BD Ultra-Fine is the most widely-cited brand in peptide community sources.

CONTOUR NEXT GEN Glucose Meter All-In-One Kit

Ascensia's CONTOUR NEXT GEN — the most clinically-validated home glucose meter. Includes 20 test strips + lancing device. Tracks the blood-sugar response GLP-1 users care about, especially during dose escalation.

As an Amazon Associate, The Peptide Catalog earns from qualifying purchases.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Optimized Dosing Formulations and Delivery Systems

Development of depot formulations capable of releasing CJC-1295 over extended periods (monthly or quarterly) could further improve convenience and compliance. Biodegradable microsphere encapsulation, subcutaneous implantable devices, and transdermal delivery systems represent potential advances in peptide delivery technology. Additionally, oral formulations utilizing permeation enhancers or nanoparticle carriers, while challenging for peptides, could revolutionize GH secretagogue therapy if bioavailability obstacles can be overcome. The integration of digital health technologies, including connected injection devices and remote monitoring platforms, may optimize protocol individualization and improve clinical outcomes. As research into peptide therapeutics advances across multiple domains, including metabolic optimization with compounds like AOD-9604 and regenerative applications, the therapeutic armamentarium for GH modulation continues to expand with increasingly sophisticated pharmacologic tools https://pubmed.ncbi.nlm.nih.gov/16352680/.
SIDE EFFECTS

Side Effects

Clinical trials reported that CJC-1295 was generally well-tolerated, with no serious adverse reactions at therapeutic doses. Common Side Effects: Injection site reactions (redness, pain, swelling) Flushing and warmth, particularly facial flushing lasting 5–10 minutes post-injection Water retention Headaches Dizziness Increased hunger Tingling or numbness in extremities Fatigue or lethargy initially Less Common Side Effects: Nausea Joint discomfort Mood changes Anxiety Flu-like symptoms Potential Concerns: The FDA has noted concerns about increased heart rate and cardiac events associated with CJC-1295. Individuals with active cancer, cardiovascular disease, or diabetes should exercise caution, as elevated GH and IGF-1 can theoretically promote cell proliferation and affect glucose metabolism.
02

Question drills

Open a question for its connected answer.

01What If the Peptide Dissolves But Looks Slightly Cloudy?+

Discard it immediately and do not proceed with injection. Cloudiness indicates either particulate contamination (bacterial, fungal, or foreign matter) or incomplete dissolution caused by degraded protein aggregates. Authentic CJC-1295 produces a solution indistinguishable from sterile water when properly reconstituted. Any visible haze means the vial is compromised. Attempting to filter the solution does not solve the problem because molecular degradation cannot be reversed, and bacterial contamination may include endotoxins that pass through standard filters.

SOURCE / realpeptides.co ↗
02What If CJC-1295 Is Combined with Resistance Training Instead of Caloric Restriction?+

Lean mass gains improve, but fat loss remains modest unless training volume creates meaningful energy expenditure. GH and IGF-1 elevation from CJC-1295 supports muscle protein synthesis and satellite cell activation, which is why the peptide appears frequently in body recomposition research. A 16-week study in trained men found CJC-1295 plus progressive overload training increased lean mass by 2.1 kg versus 0.9 kg in placebo, with fat mass declining 1.8 kg versus 0.6 kg. The anabolic signal outweighs the lipolytic signal when substrate availability is adequate. For pure fat loss research, caloric deficit paired with CJC-1295 produces stronger outcomes than training alone.

SOURCE / realpeptides.co ↗
03What If the Reconstituted Solution Develops Cloudiness or Particles After a Week in the Fridge?+

Stop using the vial immediately. Cloudiness indicates either bacterial contamination or peptide aggregation. Both render the solution unsuitable for research. Aggregation occurs when improperly stored peptides form insoluble complexes that no longer bind GHRH receptors. Particles may represent bacterial colonies or precipitated peptide fragments. Filter the solution through a 0.22-micron sterile filter if you need to confirm contamination versus aggregation, but in practice, any visible change from the clear colourless state warrants disposal.

SOURCE / realpeptides.co ↗
04Frequently Asked Questions About CJC-1295 for Growth Hormone Release+

Our team often gets excellent questions about this powerful research compound. Here are some of the most common inquiries we address:

SOURCE / realpeptides.co ↗
05What If I Miss a Scheduled CJC-1295 Injection — Should I Double the Next Dose?+

No. Administer your regular dose (200–300 mcg) as soon as you remember if fewer than 48 hours have passed since your scheduled injection time, then resume your normal twice-weekly schedule. If more than 48 hours have passed, skip the missed dose entirely and wait for your next scheduled injection day. Doubling doses creates supraphysiological GH spikes that trigger somatostatin rebound suppression, which can blunt your response to the following injection and accelerate receptor desensitization. Missing a single dose reduces weekly IGF-1 exposure by approximately 15–20%, but doubling doses to

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

What the one human CJC-1295 study found

According to PubMed, the only peer-reviewed clinical study (two randomized, placebo-controlled, double-blind ascending-dose trials over 28 and 49 days in healthy adults aged 21–61) reported dose-dependent GH increases of 2- to 10-fold and IGF-1 increases of 1.5- to 3-fold, with IGF-1 staying elevated for up to 28 days after dosing. The authors reported no serious adverse reactions and described the peptide as “relatively well tolerated” (Teichman et al., 2006, DOI). Crucially, the abstract does not publish an itemized breakdown of minor side effects or their frequencies—so any specific percentage you see quoted elsewhere is not traceable to this study. No serious adverse reactions at tested doses Over ≤7 weeks, small healthy sample only Clinical (CJC-1295, DAC) — Teichman et al., 2006 Sustained IGF-1 elevation for weeks per dose Expected pharmacodynamic effect; the basis of the long-term concern Injection-site reactions (e.g. erythema) Commonly reported for the GHRH-analog class; not itemized for CJC-1295 Clinical, related drug (tesamorelin) — Badran et al., 2026 Arthralgia, myalgia, paraesthesia (joint/muscle pain, tingling) Reported for the GHRH-analog class Insulin resistance / higher diabetes risk Not seen in the short CJC-1295 trial; documented with chronic GH/IGF-1 excess Mechanistic / observational — Thomas et al., 2021; Clayton et al., 2010 Possible cancer-promotion concern Never tested for CJC-1295; raised IGF-1 linked to slightly higher risk of some cancers Mechanistic / epidemiological — Clayton et al., 2010; Zhang et al., 2021 Unknown outcomes from the largest human trial Phase 2 (n=120, 12 weeks) terminated; no safety data published Registry — ConjuChem, NCT00267527

RESEARCH

Understanding Potential Effects in Research

Whilst CJC-1295 maintains a well-established safety profile for research purposes, investigators should understand the physiological effects that manifest during laboratory studies involving this GHRH analogue. Comprehensive knowledge of these effects enables optimal study design, accurate data interpretation, and informed observation of experimental outcomes. This information supports researchers in distinguishing between intended experimental responses and undesired adverse reactions.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

CJC-1295 vs Ipamorelin

CJC-1295 vs Ipamorelin explained: different mechanisms, why they stack so well together, dosing protocols, side effects, and which to choose.

Comparison

CJC-1295 In Vitro Research: Cell Model Comparison

Before selecting a cell line, ask what aspect of CJC-1295 biology you're investigating. Receptor pharmacology, intracellular signalling kinetics, or secretory dynamics? Each model…

Continue reading

Related articles

CJC-1295 side effects in research studies

CJC-1295 side effects in research studies Understanding Potential Effects in Research Whilst CJC-1295 maintains a well-established safety profile for research purposes, investigators should understand the physiological …

Read article